Shire’s constipation drug prucalopride is moving closer to market – advisers to the FDA have just unanimously backed it as a treatment for chronic idiopathic constipation (CIC) in adults.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.